Get the Stockscreener App
11.01
1.17%
-0.13
After Hours:
11.01
Astria Therapeutics Inc stock is traded at $11.01, with a volume of 612.15K.
It is down -1.17% in the last 24 hours and down -9.98% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$11.14
Open:
$11.05
24h Volume:
612.15K
Relative Volume:
1.55
Market Cap:
$621.52M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-4.5123
EPS:
-2.44
Net Cash Flow:
$-68.47M
1W Performance:
-9.98%
1M Performance:
-9.98%
6M Performance:
-21.78%
1Y Performance:
+47.59%
1-Day Range:
$10.85
$11.60
1-Week Range:
$10.38
$12.72
52-Week Range:
$4.26
$16.90
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
Astria Therapeutics Inc Stock (ATXS) Latest News
ATXSAstria Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema - StockTitan
Cubist Systematic Strategies LLC Invests $2.56 Million in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Driehaus Capital Management LLC Sells 15,057 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics (NASDAQ:ATXS) Earns Buy Rating from HC Wainwright - MarketBeat
Astria Therapeutics to Present at Upcoming Global Angioedema Forum - StockTitan
Financial Snapshot: Analyzing Astria Therapeutics Inc (ATXS)’s Key Ratio Metrics - The Dwinnex
ATXS’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Astria Therapeutics (NASDAQ:ATXS) Shares Gap Down to $12.50 - MarketBeat
Astria Therapeutics Inc [ATXS] Insider Morabito Christopher sells 10,000 Shares - Knox Daily
A year in review: Astria Therapeutics Inc (ATXS)’s performance in the last year - US Post News
Affinity Asset Advisors LLC Has $8.88 Million Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Affinity Asset Advisors LLC Buys 130,000 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Sold by Logos Global Management LP - Defense World
Logos Global Management LP Sells 1,744,960 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Long Term Trading Analysis for (ATXS) - Stock Traders Daily
Healthy Upside Potential: Astria Therapeutics Inc (ATXS) - SETE News
Quest Partners LLC Has $29,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astera Labs executive sells over $3.4 million in stock By Investing.com - Investing.com Canada
Investor’s Delight: Ascendis Pharma A/S ADR (ASND) Closes Strong at 148.88, Up 1.56 - The Dwinnex
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress - StockTitan
Equities Analysts Set Expectations for Ascendis Pharma A/S’s Q3 2024 Earnings (NASDAQ:ASND) - Defense World
Ascendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Seven Eight Capital LP - MarketBeat
APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com
Ascendis plans share sale for USD 300m despite promises to the contrary - MedWatch
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress - Business Wire
Ascent Resources Reports Interim Results and U.S. Expansion - TipRanks
Five Biotech Stocks Soar: Eyes on Halozyme, United Therapeutics, Harmony, Ligand, and ADMA - geneonline
SEC Form 424B5 filed by Ascendis Pharma A/S - Quantisnow
Analysts review Ascendis Pharma A/S ADR’s rating - Knox Daily
Ascendis Pharma slips after $300 mln share offering launch - XM
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs - GlobeNewswire
Charting the Course: Avidity Biosciences Inc’s RNA Stock Prospects - The InvestChronicle
Ascendis Pharma A/S ADR (ASND) did well last session? - US Post News
A History of Outperforming Analyst Forecasts and Beating the Odds: Astera Labs Inc. (ALAB) - SETE News
Ascendis Pharma A/S (NASDAQ:ASND) Given New $200.00 Price Target at The Goldman Sachs Group - Defense World
Oppenheimer raises Ascendis Pharma shares, maintains Outperform rating By Investing.com - Investing.com Canada
Ascent Resources Announces Successful Share Issuance - TipRanks
The Psychology of Astera Labs Inc. Inc. (ALAB) Price Performance: Understanding Market Sentiment - The InvestChronicle
Prepare Yourself for Liftoff: Ascendis Pharma A/S ADR (ASND) - SETE News
Avidity Biosciences Inc (RNA) can make a big difference with a little luck - SETE News
Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last? - Yahoo Finance
Avidity Biosciences (NASDAQ:RNA) Given “Overweight” Rating at Cantor Fitzgerald - Defense World
Sofinnova Investments Inc. Invests $552,000 in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Sofinnova Investments Inc. Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Ascendis Pharma price target raised to $190 from $180 at Oppenheimer - TipRanks
Quest Partners LLC Raises Stock Position in Armada Hoffler Properties, Inc. (NYSE:AHH) - Defense World
Unveiling 7 Analyst Insights On Avidity Biosciences - Benzinga
Market Watch: Avidity Biosciences Inc (RNA)’s Noteworthy Gain, Closing at 41.71 - The Dwinnex
Positive topline data supports Ascendis Pharma stock, analyst highlights potential for weekly injection advantage. - Investing.com
Ascendis rises on positive trial data for dwarfism therapy - XM
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):